Goldman Sachs’s PTC Therapeutics PTCT Stock Holding History

Goldman Sachs’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27,500	Closed	-$1.4M	–	5504
2020 Q2	$1.4M	Buy	+27,500	New	+$1.35M	﹤0.01%	3728
2017 Q3	–	Sell	-20,000	Closed	-$367K	–	6810
2017 Q2	$367K	Sell	20,000 -305,000	-94%	-$4.11M	﹤0.01%	5339
2017 Q1	$3.2M	Buy	+325,000	New	+$3.93M	﹤0.01%	3319
2016 Q4	–	Sell	-300,000	Closed	-$4.2M	–	7040
2016 Q3	$4.2M	Buy	+300,000	New	+$2.44M	﹤0.01%	3193
2016 Q1	–	Sell	-96,300	Closed	-$3.12M	–	7268
2015 Q4	$3.12M	Sell	96,300 -406,300	-81%	-$12M	﹤0.01%	3246
2015 Q3	$13.4M	Buy	502,600 +473,500	+1,627%	+$20.3M	﹤0.01%	2017
2015 Q2	$1.4M	Sell	29,100 -8,600	-23%	-$502K	﹤0.01%	4208
2015 Q1	$2.29M	Buy	+37,700	New	+$2.3M	﹤0.01%	3652

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs's PTCT Position: Q1 2026 in Review

Goldman Sachs reduced its PTC Therapeutics (PTCT) stake by 19% in Q1 2026, selling an estimated $13.8M and leaving 827,631 shares worth $56.4M. The position accounts for 0.01% of the portfolio, ranked #1484.

Goldman Sachs first reported a position in PTCT in Q3 2013 and has held it in 49 quarters since. The position peaked at $77.7M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Goldman Sachs held 827,631 shares of PTC Therapeutics worth $56.4M as of Q1 2026.
Goldman Sachs sold 195,460 PTC Therapeutics shares in Q1 2026, an estimated $13.8M.
PTC Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1484 holding.
Goldman Sachs first reported a position in PTC Therapeutics in Q3 2013 and has held it in 49 quarters since.
Goldman Sachs's PTC Therapeutics position peaked at $77.7M in Q4 2025.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.